N/A
Completed N=121
Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness
Source: ClinicalTrials.gov NCT02029989 ↗Enrolled (actual)
121
Serious AEs
0.0%
Results posted
May 2014
Primary outcomePrimary: Metabolic Syndrome (MetS) — 85.2; 71.2 percentage of participants
Summary
The study was a 12-month, multi-centered, quasi-experimental design to assess point-of-care (POCT) screening/monitoring of subjects on antipsychotic agents for metabolic syndrome. Subjects were also randomized to either an Extended Treatment Group (ETG) defined by receiving comprehensive medication management (CMM) pharmacist interventions or a Usual Treatment Group (UTG) receiving no CMM interventions. All subjects were recruited from three community mental health clinic settings in Minnesota.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Metabolic Syndrome (MetS) |
85.2; 71.2 | — |
Eligibility Criteria
Inclusion Criteria
- English speaking
- Age 18-64
- Competent to understand and make medical choices independently
Exclusion Criteria
- Currently or previously seen by a CMM pharmacist
Data sourced from ClinicalTrials.gov (NCT02029989). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.